Articles by Leah Lawrence
Obesity is a chronic, complex disease driven by biology, not just behavior—effective care requires empathy and support.
TLR9 gene variants may influence vitiligo risk, new research suggests innate immunity plays a key role.
Elevated bilirubin levels may lower vitiligo risk, suggesting a protective role, new genetic study finds.
Tofacitinib shows promising 6-month results for alopecia totalis and universalis, with notable hair regrowth and safety profi
Topical JAK inhibitors show promise for vitiligo, but current evidence lacks strong statistical support, study finds.
Ifetroban shows significant 12-month cardiac benefit in DMD patients, per phase-2 FIGHT DMD trial results.
Apitegromab improves motor function in SMA patients aged 2–21, per phase-3 SAPPHIRE trial results.
Losmapimod failed to show clinical benefit over placebo in FSHD patients in the phase 3 REACH trial, ending its development.
Intrathecal gene therapy OA significantly improved motor function in older SMA patients in phase-3 STEER trial.
iDFS strongly correlates with OS in HR+/HER2- early breast cancer, supporting its use as a surrogate endpoint in trials.
Sacituzimab govitecan showed modest CNS activity in pretreated HER2-negative metastatic breast cancer with brain metastases.
Shorter chemoimmunotherapy shows promise in early TNBC, with higher pCR in PD-L1+ or TIL-high patients, Neo-N trial finds.
Imlunestrant with or without abemaciclib improved PFS in ER+/HER2- advanced breast cancer post-endocrine therapy.
The FDA approved trastuzumab deruxtecan for HR-positive/HER2-low metastatic breast cancer based on DESTINY-Breast06 results.
The FDA granted Fast Track status to emiltatug ledadotin for advanced breast cancer following phase 1 results targeting B7-H4
Researchers compared outcomes between patients with baseline stage III N2 and non-N2 NSCLC.
A pilot study evaluated neoadjuvant platinum, pemetrexed, and nivolumab followed by pleurectomy/decortication.
Study investigators say the results support further study of the bispecific T-cell engager in previously treated SCLC.
An analysis of the phase 3 trial evaluated multiple aspects of health-related quality of life.
The study "confirmed the role of adagrasib compared to docetaxel" in terms of PFS, response rate, and intracranial response.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.